S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
NASDAQ:PNT

POINT Biopharma Global (PNT) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$12.49
$12.51
50-Day Range
$12.45
$14.23
52-Week Range
$6.57
$14.35
Volume
3.29 million shs
Average Volume
1.44 million shs
Market Capitalization
$1.33 billion
P/E Ratio
13.89
Dividend Yield
N/A
Price Target
$12.80

POINT Biopharma Global MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
2.4% Upside
$12.80 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.69) to ($0.68) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.28 out of 5 stars

Medical Sector

931st out of 958 stocks

Pharmaceutical Preparations Industry

406th out of 415 stocks


PNT stock logo

About POINT Biopharma Global Stock (NASDAQ:PNT)

POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.


PNT Stock News Headlines

Lilly Completes Acquisition of POINT Biopharma
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Piper Sandler Keeps Their Hold Rating on POINT Biopharma Global (PNT)
Recap: POINT Biopharma Global Q3 Earnings
Lilly Extends Tender Offer For POINT Biopharma Global Until Nov. 16
See More Headlines
Receive PNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for POINT Biopharma Global and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
2/28/2024
Next Earnings (Estimated)
3/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PNT
Fax
N/A
Employees
129
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.80
High Stock Price Target
$14.00
Low Stock Price Target
$12.50
Potential Upside/Downside
+2.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
10 Analysts

Profitability

Net Income
$98.29 million
Pretax Margin
52.16%

Debt

Sales & Book Value

Annual Sales
$226.58 million
Cash Flow
$0.94 per share
Book Value
$4.68 per share

Miscellaneous

Free Float
89,518,000
Market Cap
$1.33 billion
Optionable
Optionable
Beta
N/A
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Allan Charles Silber (Age 73)
    Executive Chairman
    Comp: $1.02M
  • Dr. Joe A. McCann Ph.D. (Age 45)
    CEO & Director
    Comp: $1.06M
  • Dr. Neil E. Fleshner FRCSC (Age 59)
    M.D., M.PH, Chief Medical Officer & Director
    Comp: $318.49k
  • Ms. Jessica D. Jensen M.P.H. (Age 43)
    Executive Vice President of Clinical Development
    Comp: $816.17k
  • Mr. Bill Demers B.B.A. (Age 64)
    F.C.A., FCPA, CFO & Corporate Secretary
    Comp: $78.26k
  • Ms. Justyna Kelly M.Sc. (Age 38)
    Chief Operating Officer
  • Ms. Jazz Braich
    SVP of People & Culture
  • Mr. Ari Shomair
    VP of Corporate Affairs & Chief of Staff
  • Dr. Myra Rosario Herle Ph.D.
    R.Ph., Executive Vice President of Regulatory Affairs
  • Dr. Matthew P. Vincent J.D.
    Ph.D., Senior Vice President of Business Development














PNT Stock Analysis - Frequently Asked Questions

Should I buy or sell POINT Biopharma Global stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for POINT Biopharma Global in the last year. There are currently 10 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PNT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PNT, but not buy additional shares or sell existing shares.
View PNT analyst ratings
or view top-rated stocks.

What is POINT Biopharma Global's stock price target for 2024?

10 Wall Street analysts have issued 12-month price targets for POINT Biopharma Global's shares. Their PNT share price targets range from $12.50 to $14.00. On average, they predict the company's share price to reach $12.80 in the next year. This suggests a possible upside of 2.4% from the stock's current price.
View analysts price targets for PNT
or view top-rated stocks among Wall Street analysts.

When is POINT Biopharma Global's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 25th 2024.
View our PNT earnings forecast
.

How were POINT Biopharma Global's earnings last quarter?

POINT Biopharma Global Inc. (NASDAQ:PNT) posted its quarterly earnings results on Monday, November, 13th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.07. The firm had revenue of $2.79 million for the quarter, compared to analysts' expectations of $8 million. POINT Biopharma Global had a trailing twelve-month return on equity of 21.10% and a net margin of 39.62%.

Who are POINT Biopharma Global's major shareholders?

POINT Biopharma Global's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Clear Street Markets LLC (0.00%), Perceptive Advisors LLC (0.00%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Allan C Silber, Bvf Partners L P/Il, Joe A Mccann, Jonathan R Goodman, Neil E Fleshner and Yael Margolin.
View institutional ownership trends
.

This page (NASDAQ:PNT) was last updated on 2/29/2024 by MarketBeat.com Staff